For how we live.
In 62 adults scanned under psilocybin during rest, meditation, music, and film, brain networks reorganized differently by setting — and more reorganization tracked with more positive experiences.
Anxiety, quality of life and PTSD symptoms all improved after a single dose in this 15-person trial. Once researchers accounted for depression improvement, those effects mostly disappeared.
Switzerland allows limited psilocybin use for treatment-resistant depression. A review of 19 patients found meaningful improvement, but remission in barely a fifth to a quarter.
A review pooling 23 studies found risk concentrated among people with bipolar I disorder, family history, or unsupervised use. About 4% later transitioned to bipolar disorder.
By the study's end, 70% had scores low enough to be considered near-resolution. There was no placebo arm — every participant knew what they'd received.
EPISODE randomized 144 people with treatment-resistant depression across four arms. High-dose psilocybin missed its main outcome, even as secondary measures showed symptom benefit.
No medication has proven effective for cocaine use disorder. A single psilocybin dose, paired with therapy, produced more abstinent days and a longer time to relapse than an active placebo.
In 35 patients with recurrent major depression, psilocybin beat an active placebo through day 42. On self-reported measures the effect lingered further, but the trial's primary endpoint showed no difference at 365 days.
Twenty-four healthy volunteers received all three drugs in a crossover trial. At 30 mg, 2C-B matched MDMA's intensity and produced psilocybin-like states, without psilocybin's anxiety.
The first federal survey to ask about psilocybin specifically finds 2.8% past-year use, concentrated among young, white, college-educated men. People with recent depression had 37% higher odds.
The open-label pilot tested a specific worry in psychedelic research — that borderline personality disorder blunts response to psilocybin for depression. In this small sample, it didn't.
Up to eight sessions of psilocybin, layered onto a small randomized comparison against an active placebo, produced a 73% response rate by the end of treatment. The trial was designed to test safety first.
Six months out, 40.5% of smokers given one high dose of psilocybin plus therapy stayed abstinent, versus 10% on the nicotine patch plus the same therapy. The trial ran 82 people.
Pooling 31 studies of 556 patients, cortical 5-HT2A binding was lower in unmedicated depression than in controls. The post-mortem studies mostly found nothing, and the tracers used shape the result.